Malignant Exocrine Pancreas Neoplasm — Trials

Malignant Exocrine Pancreas Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

930 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 360
Recruiting: 209
Ph III recruiting: 23
Growth YoY: +39.4%
Industry share: 40%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (136)

clinicaltrialsPublishedShowing 101–150 of 166 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05431270	Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)	recruiting	Phase 1 / Phase 2	40	Phanes TherapeuticsINDUSTRY	1	May 19, 2026	clinicaltrials
NCT06904378	ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma	recruiting	Phase 1 / Phase 2	61	Washington University School of MedicineOTHER	1	May 19, 2026